Invention Grant
- Patent Title: Tetrameric cytokines with improved biological activity
- Patent Title (中): 具有改善的生物活性的四聚体细胞因子
-
Application No.: US13219940Application Date: 2011-08-29
-
Publication No.: US08597659B2Publication Date: 2013-12-03
- Inventor: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant Address: US NJ Morris Plains
- Assignee: IBC Pharmaceuticals, Inc.
- Current Assignee: IBC Pharmaceuticals, Inc.
- Current Assignee Address: US NJ Morris Plains
- Agent Richard A. Nakashima
- Main IPC: A61K39/44
- IPC: A61K39/44 ; A61K39/00 ; A61K38/18 ; A61K38/20 ; A61K38/21 ; A61K39/385 ; C07K16/28 ; C07K16/30 ; C07K14/505 ; C07K14/535 ; C07K14/56 ; A61K39/395 ; C07K16/44

Abstract:
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.
Public/Granted literature
- US20120009149A1 Tetrameric Cytokines with Improved Biological Activity Public/Granted day:2012-01-12
Information query